Trigeminal Nerve Stimulation - An Integrated Neuromodulation Platform

NeuroSigma, Inc. is developing and commercializing trigeminal nerve stimulation (TNS) for a variety of neurologic and psychiatric disorders. TNS is unique among neuromodulation therapies because it can be delivered via a non-invasive external trigeminal nerve stimulation (eTNS™) system, or a minimally-invasive subcutaneous trigeminal nerve stimulation (sTNS™) system. NeuroSigma is investigating TNS as a treatment for epilepsy, depression, attention deficit hyperactivity disorder (ADHD), and post-traumatic stress disorder (PTSD).

The Monarch™ eTNS system is NeuroSigma’s lead product and has received approval in the European Union and Canada as a treatment for epilepsy and depression. For more information on the Monarch, please visit our specialty site.

   

External Trigeminal Nerve Stimulation (eTNS™)

External Trigeminal Nerve Stimulation (eTNS™)

Subcutaneous Trigeminal Nerve Stimulation (sTNS™)

Subcutaneous Trigeminal Nerve Stimulation (sTNS™)

 

CAUTION: In the United States, both eTNS™ and sTNS™ are investigational devices and are limited by Federal (or United States) law to investigational use.